Characteristics of patients with NLPHL and patients with cHL treated in the HD16 and HD17 studies
| . | HD16 . | HD17 . | ||||
|---|---|---|---|---|---|---|
| NLPHL (n = 85) . | cHL (n = 495) . | P value . | NLPHL (n = 15) . | cHL (n = 764) . | P value . | |
| Median age, y (range) | 37 (19-71) | 36 (18-75) | .4380 | 42 (23-59) | 31 (18-60) | .3967 |
| Males | 62 (72.9%) | 254 (51.3%) | .0002 | 13 (86.7%) | 337 (44.1%) | .0011 |
| Stage II | 81 (95.3%) | 464 (93.7%) | .8051 | 15 (100%) | 720 (94.2%) | 1.0000 |
| B symptoms | 12 (14.1%) | 64 (12.9%) | .7298 | 2 (13.3%) | 189 (24.7%) | .5433 |
| ECOG PS 0 | 81 (95.3%) | 452 (91.3%) | .2829 | 15 (100%) | 635 (83.1%) | .1502 |
| Infradiaphragmatic disease | 22 (25.9%) | 45 (9.1%) | <.0001 | 7 (46.7%) | 43 (5.6%) | <.0001 |
| Mediastinal involvement | 5 (5.9%) | 183 (37%) | <.0001 | 4 (26.7%) | 674 (88.2%) | <.0001 |
| Large mediastinal mass | — | — | — | 0 (0%) | 137 (17.9%) | .0868 |
| Extranodal involvement | — | — | — | 2 (13.3%) | 57 (7.5%) | .3162 |
| Involvement of ≥3 nodal areas | — | — | — | 14 (93.3%) | 556 (72.8%) | .0834 |
| Elevated ESR | — | — | — | 0 (0%) | 350 (45.8%) | .002 |
| Typical growth pattern | 44 of 67 (65.7%) | — | — | 7 of 10 (70%) | — | — |
| Positive interim PET | 39 (45.9%) | 171 (34.5%) | .0507 | 3 (20%) | 246 (32.2%) | .4097 |
| DS 3 | 18 of 39 (46.2%) | 109 of 171 (63.7%) | 2 of 3 (66.7%) | 181 of 246 (73.6%) | ||
| DS 4 | 21 of 39 (53.8%) | 62 of 171 (36.3%) | 1 of 3 (33.3%) | 65 of 246 (26.4%) | ||
| . | HD16 . | HD17 . | ||||
|---|---|---|---|---|---|---|
| NLPHL (n = 85) . | cHL (n = 495) . | P value . | NLPHL (n = 15) . | cHL (n = 764) . | P value . | |
| Median age, y (range) | 37 (19-71) | 36 (18-75) | .4380 | 42 (23-59) | 31 (18-60) | .3967 |
| Males | 62 (72.9%) | 254 (51.3%) | .0002 | 13 (86.7%) | 337 (44.1%) | .0011 |
| Stage II | 81 (95.3%) | 464 (93.7%) | .8051 | 15 (100%) | 720 (94.2%) | 1.0000 |
| B symptoms | 12 (14.1%) | 64 (12.9%) | .7298 | 2 (13.3%) | 189 (24.7%) | .5433 |
| ECOG PS 0 | 81 (95.3%) | 452 (91.3%) | .2829 | 15 (100%) | 635 (83.1%) | .1502 |
| Infradiaphragmatic disease | 22 (25.9%) | 45 (9.1%) | <.0001 | 7 (46.7%) | 43 (5.6%) | <.0001 |
| Mediastinal involvement | 5 (5.9%) | 183 (37%) | <.0001 | 4 (26.7%) | 674 (88.2%) | <.0001 |
| Large mediastinal mass | — | — | — | 0 (0%) | 137 (17.9%) | .0868 |
| Extranodal involvement | — | — | — | 2 (13.3%) | 57 (7.5%) | .3162 |
| Involvement of ≥3 nodal areas | — | — | — | 14 (93.3%) | 556 (72.8%) | .0834 |
| Elevated ESR | — | — | — | 0 (0%) | 350 (45.8%) | .002 |
| Typical growth pattern | 44 of 67 (65.7%) | — | — | 7 of 10 (70%) | — | — |
| Positive interim PET | 39 (45.9%) | 171 (34.5%) | .0507 | 3 (20%) | 246 (32.2%) | .4097 |
| DS 3 | 18 of 39 (46.2%) | 109 of 171 (63.7%) | 2 of 3 (66.7%) | 181 of 246 (73.6%) | ||
| DS 4 | 21 of 39 (53.8%) | 62 of 171 (36.3%) | 1 of 3 (33.3%) | 65 of 246 (26.4%) | ||
ECOG PS, Eastern Cooperative Oncology Group performance status; ESR, erythrocyte sedimentation rate.